Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas - Wikidata - awgldk - TriplyDB

Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas

Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas

http://www.wikidata.org/entity/Q34230978

about

Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy Delafloxacin: design, development and potential place in therapy Delafloxacin for the treatment of respiratory and skin infections.Efficacy of increasing dosages of clarithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia.Pharmacokinetics and bioavailability of doxycycline in ostriches (Struthio camelus) at two different dose rates Levofloxacin in the treatment of community-acquired pneumonia.In Vitro Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Nonsusceptible Staphylococcus aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections New Horizons in Mycoplasma genitalium Treatment.Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy New treatment options for lower respiratory tract infections.In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014 In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas.What Is Old Is New Again: Delafloxacin, a Modern Fluoroquinolone.Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin.

P2860

Q26824268-8B2577BB-DBAC-4404-B342-C5F09D9B7A9B Q34554381-638160E6-9463-4EEF-976A-05C59F5292F7 Q34667588-47AB7143-4292-4237-B0D5-478332606961 Q35210467-3832677A-0730-4E89-BB76-5D72F67F82F1 Q35622439-C59CD12A-1234-4586-9A96-E493E716CF15 Q37747381-20D71704-84C9-42D7-AD97-D541B3503D60 Q38375319-469D144E-519A-4FD0-BA29-2AA8816DA53B Q38609857-D9748DCE-19B8-48E4-898D-2C31A5CAC583 Q38842229-01EB62E2-589F-4A17-9FC1-4447EDDB4319 Q40111519-81D8112E-5F61-4098-82C3-467BCF45F840 Q40342746-329962CE-767D-4586-A448-83CD8B5C116C Q41194442-D47ECB74-E07B-4B3F-BF01-EB5C089D67E9 Q41269280-A000319E-C5EE-4EC3-B665-96F70B9F2799 Q47736241-3C76A497-B02F-439D-9A23-E5CB583EE71E Q52579373-76FB1243-E00B-4C49-AD28-70D20A2C8A60

P2860

Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas

http://www.wikidata.org/entity/Q34230978

description

2003 nî lūn-bûn

@nan

2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Comparative in vitro susceptib ...... an mycoplasmas and ureaplasmas

@ast

Comparative in vitro susceptib ...... an mycoplasmas and ureaplasmas

@en

Comparative in vitro susceptib ...... an mycoplasmas and ureaplasmas

@nl

type

label

Comparative in vitro susceptib ...... an mycoplasmas and ureaplasmas

@ast

Comparative in vitro susceptib ...... an mycoplasmas and ureaplasmas

@en

Comparative in vitro susceptib ...... an mycoplasmas and ureaplasmas

@nl

prefLabel

Comparative in vitro susceptib ...... an mycoplasmas and ureaplasmas

@ast

Comparative in vitro susceptib ...... an mycoplasmas and ureaplasmas

@en

Comparative in vitro susceptib ...... an mycoplasmas and ureaplasmas

@nl

P1433

Q34230978-F729CAC7-833A-4B0F-B8DB-AC87F38B82D0

P1476

Q34230978-46F503B9-4C3A-46F9-B68A-A52728D5889E

P2093

Q34230978-432C975E-B9B7-47CA-B3E7-A3DFCC189B5E

Q34230978-DBDBBFE1-C476-4635-BF2A-8250193C025F

Q34230978-F8EA7F3E-57AA-45EE-AF59-72D8C0A37240

P2860

Q34230978-24DBE607-0438-4D11-B39B-EA7E2278DEA8

Q34230978-5A820E6D-F75E-49F7-BDDC-BAFB49035A7B

Q34230978-67C3F6D8-DE78-413E-81C5-CA6171980238

Q34230978-701E8C3D-907B-47C0-B8AB-D77079B80200

Q34230978-8A3EB7F9-8344-4E4B-866F-47699856654C

Q34230978-9457F8C8-5704-4C82-950C-D70018E44E21

Q34230978-95FEF57C-4C21-46D2-9F33-3E1B94F45715

Q34230978-C70982B9-77B3-4F7B-AF65-9F20C9988511

Q34230978-E332755A-FA13-4E09-88D2-2B89741CD4E3

Q34230978-F6A5C4C6-7A36-460D-B082-80217CF405B5

P304

Q34230978-068E0DC9-12F3-4C16-86C1-103A516F3C06

P31

Q34230978-79D99043-0B1F-46CF-A4FA-50C841DC20B6

P356

Q34230978-76D47AEC-4BF2-4EB0-9E82-91EF9F2CFE86

P407

Q34230978-CC9CD155-CEBC-4E03-A6E1-D0E9381C1CC1

P433

Q34230978-6544A12F-FF1F-4B44-B93E-1E2526C53277

P478

Q34230978-08A5AE01-ACCB-4A46-890A-0F0B298EFAD0

P577

Q34230978-4D02008B-AA1D-4D26-A6D5-8BD130B80EE0

P5875

Q34230978-FA4E7CA8-B44F-4938-9CE1-1B553D97628F

P698

Q34230978-3DDC3556-CDAE-4D96-B526-91893DD49ED6

P932

Q34230978-3FA3AFA8-033F-4878-A804-16D7D532E50D

P356

AAC.47.12.3973-3975.2003

P1433

Antimicrobial Agents and Chemotherapy

P1476

Comparative in vitro susceptib ...... an mycoplasmas and ureaplasmas

@en

P2093

Donna M Crabb

http://www.w3.org/2001/XMLSchema#string

Ken B Waites

http://www.w3.org/2001/XMLSchema#string

Lynn B Duffy

http://www.w3.org/2001/XMLSchema#string

P2860

In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas

Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002

Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002

Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method.

In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis

In vitro susceptibilities of Mycoplasma hominis to six fluoroquinolones as determined by E test.

Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas.

In vitro activities of moxifloxacin and other fluoroquinolones against Mycoplasma pneumoniae.

Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibil

In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas.

P304

3973-3975

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.47.12.3973-3975.2003

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2003-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8990311

http://www.w3.org/2001/XMLSchema#string

P698

14638513

http://www.w3.org/2001/XMLSchema#string

P932

296221

http://www.w3.org/2001/XMLSchema#string